InterMune (nasdaq)ITMN Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : InterMune (nasdaq)ITMN

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: IRWIN JAMES FRANKEL who wrote (92)	4/27/2001 2:23:40 PM
From: IRWIN JAMES FRANKEL	of 508

More on the CC. I got a few minutes today to go back and listen to the whole CC. Here is a link to the replay (StreetFusion Web cast): investor.intermune.com There were some interesting points that I missed in my earlier post: - expect to complete enrollment in IPF study in late July, or 3Q - sales staff have option and cash incentives to complete enrollment - time from diagnosis to getting on Actimunne 2wks to 8 wks - 80% of requests to 3rd party payers for reimbursement of Actimunne in IPF patients are being approved on the 1st try (this one amazes me - so maybe I misunderstood) - about 150 to 200 doctors are now treating IPF with Actimunne - relevant doctors to market to: - - pulmonologists, 7,000 - - ID docs, 4,500 - - oncologists 7,000 - in 4-8 weeks the company will launch the IPF treatment registry - favorable anecdotal evidence on Actimunne is accumulating - very late stage use of Actimunne in IPF does not rescue those who are near death As always, I try to report accurately what I hear and may or may not get it right. I welcome and appreciate others correcting or adding to an understanding of the CC. ij

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next